BridgeMD
Tests treatment safety and results for Social Anxiety Disorder (SAD)
Official title Efficacy of Attention Bias Modification vs. Placebo for Social Anxiety Disorder
ClinicalTrials.gov ID: NCT07666776
What this study is testing
- What it's testing
- This study examines whether a computerized attention-training intervention called attention bias modification (ABM) can reduce symptoms of social anxiety disorder (SAD) in adults, and whether symptom improvement is specifically related to changes in attentional processing or to nonspecific factors such as expectancy and placebo effects.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Adults aged 18-65 years
- Primary diagnosis of generalized Social Anxiety Disorder based on clinical evaluation, the MINI International Neuropsychiatric Interview (MINI), and...
- Normal or corrected-to-normal vision without color blindness
- Sufficient Hebrew proficiency to complete clinical interviews, self-report questionnaires, and computerized cognitive tasks
You likely can't join if
- Previous participation in attention bias modification training using a dot-probe task
- Previous participation in eye-tracking-based attention training
- Current diagnosis of Post-Traumatic Stress Disorder
- Current or past diagnosis of psychotic disorder or bipolar disorder
- Neurological disorder (e.g., epilepsy or traumatic brain injury)
- Severe suicidal ideation
See the full eligibility criteria
- Adults aged 18-65 years
- Primary diagnosis of generalized Social Anxiety Disorder based on clinical evaluation, the MINI International Neuropsychiatric Interview (MINI), and a Liebowitz Social Anxiety Scale (LSAS) score greater than 50
- Normal or corrected-to-normal vision without color blindness
- Sufficient Hebrew proficiency to complete clinical interviews, self-report questionnaires, and computerized cognitive tasks
- Previous participation in attention bias modification training using a dot-probe task
- Previous participation in eye-tracking-based attention training
- Current diagnosis of Post-Traumatic Stress Disorder
- Current or past diagnosis of psychotic disorder or bipolar disorder
- Neurological disorder (e.g., epilepsy or traumatic brain injury)
- Severe suicidal ideation
- Current substance or alcohol use disorder
- Concurrent pharmacological or psychosocial treatment, unless medication has been stable for at least 45 days
- Pregnancy
- Uncorrected visual impairment or use of multifocal glasses
The study team makes the final eligibility decision.
Where it's taking place
- Tel Aviv, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tel Aviv, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.